Passage BIO, Inc.·4

Apr 20, 4:28 PM ET

King Simona 4

4 · Passage BIO, Inc. · Filed Apr 20, 2023

Insider Transaction Report

Form 4
Period: 2023-04-18
King Simona
Chief Financial Officer
Transactions
  • Exercise/Conversion

    Restricted Stock Units

    2023-04-186,25018,750 total
    Common Stock (6,250 underlying)
  • Exercise/Conversion

    Common Stock

    2023-04-18+6,2506,250 total
  • Sale

    Common Stock

    2023-04-18$1.05/sh2,053$2,1562,053 total
Footnotes (4)
  • [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
  • [F2]The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
  • [F3]1/4 of the RSUs vested on April 18, 2023, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
  • [F4]These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION